Concurrent versus Sequential Sorafenib Therapy in Combination with Radiation for Hepatocellular Carcinoma

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Wild, Aaron T ^a   Gandhi, Nishant ^a   Chettiar, Sivarajan T ^a   Aziz, Khaled ^a   Gajula, Rajendra P ^a   Williams, Russell D ^a   Kumar, Rachit ^a   Taparra, Kekoa ^a   Zeng, Jing ^a   Cades, Jessica A ^b   Velarde, Esteban ^a   Menon, Siddharth ^a   Geschwind, Jean F ^b   Cosgrove, David ^a   Pawlik, Timothy M ^b   Maitra, Anirban ^b   Wong, John ^a   Hales, Russell K ^a   Torbenson, Michael S ^b   Herman, Joseph M ^a   Tran, Phuoc T ^a,b   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; HISTONE H2AX; HISTONE H2AX GAMMA; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; H2AFX PROTEIN, HUMAN; HISTONE; NICOTINAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CHEMORADIOTHERAPY; CLONOGENESIS; CONTROLLED STUDY; DNA STRAND BREAKAGE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MITOSIS INDEX; MOUSE; NONHUMAN; RADIATION PROTECTION; RADIOSENSITIVITY; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CLINICAL TRIAL (TOPIC); DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; DRUG SCREENING; GAMMA RADIATION; GENE EXPRESSION; GENETICS; HINDLIMB; LIVER NEOPLASMS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; PROCEDURES; RADIATION DOSE; RADIATION RESPONSE; THERAPEUTIC USE; TUMOR CELL LINE; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DNA BREAKS, DOUBLE-STRANDED; GAMMA RAYS; GENE EXPRESSION; HINDLIMB; HISTONES; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; RADIATION TOLERANCE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878772419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065726     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. El-Serag HB, (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118-1127.
3. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, et al. (2000) Hepatitis C virus related cirrhosis: Time to occurrence of hepatocellular carcinoma and death. Gut 47: 131-136.
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the united states, 1999 through 2002. Ann Intern Med 144: 705-714.
5. Wasley A, Grytdal S, Gallagher K, (2008) Centers for Disease Control and Prevention (2008) Surveillance for acute viral hepatitis-United States, 2006 Morbidity and Mortality Weekly Report. Surveillance Summaries (Washington, D.C.: 2002) 57: 1-24.
6. Surveillance, epidemiology, and end results (SEER) program (2010) SEER*Stat database: Incidence - SEER 9 regs research data, Nov 2009 sub (1973-2007). Bethesda, MD: National Cancer Institute.
7. London WT, McGlynn KA (2006) Liver cancer. In Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention, edition 3. new york, NY: Oxford university press. pp. 763-786.
8. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
9. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. (2009) Efficacy and safety of sorafenib in patients in the asia-pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34.
10. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109.
11. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, et al. (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7: 3129-3140.
12. Liu L, Cao Y, Chen C, Zhang X, McNabola A, et al. (2006) Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-8.
13. Chang YS, Adnane J, Trail PA, Levy J, Henderson A, et al. (2007) Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59: 561-574.
14. Murphy DA, Makonnen S, Lassoued W, Feldman MD, Carter C, et al. (2006) Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am J Pathol 169: 1875-1885.
15. Kim S, Yazici YD, Calzada G, Wang ZY, Younes MN, et al. (2007) Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 6: 1785-1792.
16. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, et al. (2007) Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282: 29230-29240.
17. Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, et al. (2003) Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: Its role in tumor progression and apoptosis. BMC Gastroenterol 3: 19.
18. Sugimoto K, Moriyasu F, Shiraishi J, Saito K, Taira J, et al. (2012) Assessment of arterial hypervascularity of hepatocellular carcinoma: Comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur Radiol 22: 1205-13.
19. Choi BI, Lee JM, (2010) Advancement in HCC imaging: Diagnosis, staging and treatment efficacy assessments: Imaging diagnosis and staging of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 17: 369-373.
20. Xie B, Wang DH, Spechler SJ, (2012) Sorafenib for treatment of hepatocellular carcinoma: A systematic review. Dig Dis Sci 57: 1122-9.
21. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, et al. (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 304: 2154-2160.
22. Sanoff HK, Bernard S, Goldberg RM, Morse MA, Garcia R, et al. (2011) Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res 4: 78-83.
23. Hsu CH, Shen YC, Lin ZZ, Chen PJ, Shao YY, et al. (2010) Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 53: 126-131.
24. Petrini I, Lencioni M, Ricasoli M, Iannopollo M, Orlandini C, et al. (2011) Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 69: 773-80.
25. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, et al. (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol pp. 3960-3967.
26. Park JW, Koh YH, Kim HB, Kim HY, An S, et al. (2012) Phase II study of concurrent transarterial chemoembolization and sorafenib for patients with unresectable hepatocellular carcinoma. J Hepatol 56: 1336-42.
27. Qu X, Chen C, Wang J, Yan Z, Chen J, et al. (2012) The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer 12: 263.
28. Cao Z, Fan-Minogue H, Bellovin DI, Yevtodiyenko A, Arzeno J, et al. (2011) MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 71: 2286-2297.
29. Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, et al. (2007) Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67: 9443-9454.
30. Wong J, Armour E, Kazanzides P, Iordachita I, Tryggestad E, et al. (2008) High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. International Journal of Radiation Oncology, Biology, Physics 71: 1591-1599.
31. Fertil B, Dertinger H, Courdi A, Malaise EP, (1984) Mean inactivation dose: A useful concept for intercomparison of human cell survival curves. Radiat Res 99: 73-84.
32. Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, et al. (2008) The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 14: 5142-5149.
33. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ, (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11: 5472-5480.
34. Albelda SM, Muller WA, Buck CA, Newman PJ, (1991) Molecular and cellular properties of PECAM-1 (endoCAM/CD31): A novel vascular cell-cell adhesion molecule. J Cell Biol 114: 1059-1068.
35. Gerdes J, (1985) An immunohistological method for estimating cell growth fractions in rapid histopathological diagnosis during surgery. Int J Cancer 35: 169-171.
36. Li Q, Hu Y, Xi M, He L, Zhao L, et al. (2012) Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner. BMC Cancer 12: 485.
37. Heim M, Scharifi M, Zisowsky J, Jaehde U, Voliotis D, et al. (2005) The raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 16: 129-136.
38. Tersima T, Tolmach LJ, (1961) Changes in x-ray sensitivity of HeLa cells during the division cycle. Nature 190: 1210-1211.
39. Terasima T, Tolmach LJ, (1963) X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140: 490-492.
40. Stobbe CC, Park SJ, Chapman JD, (2002) The radiation hypersensitivity of cells at mitosis. Int J Radiat Biol 78: 1149-1157.
41. Hill AA, Wan F, Acheson DK, Skarsgard LD, (1999) Lack of correlation between G1 arrest and radiation age-response in three synchronized human tumour cell lines. Int J Radiat Biol 75: 1395-1408.
42. Biade S, Stobbe CC, Chapman JD, (1997) The intrinsic radiosensitivity of some human tumor cells throughout their cell cycles. Radiat Res 147: 416-421.
43. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, et al. (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563.
44. Zaidi S, McLaughlin M, Bhide SA, Eccles SA, Workman P, et al. (2012) The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PLoS One 7: e35436.
45. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, et al. (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701-708.
46. Chen H, Ma Z, Vanderwaal RP, Feng Z, Gonzalez-Suarez I, et al. (2011) The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res 175: 214-224.